207 related articles for article (PubMed ID: 37600707)
1. Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
Ye Y; Luo Y; Guo T; Zhang C; Sun Y; Xu A; Ji L; Ou J; Wu SY
Front Endocrinol (Lausanne); 2023; 14():1179050. PubMed ID: 37600707
[TBL] [Abstract][Full Text] [Related]
2. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Luo Y; Ye Y; Chen Y; Zhang C; Sun Y; Wang C; Ou J
Front Immunol; 2023; 14():1140993. PubMed ID: 36993976
[TBL] [Abstract][Full Text] [Related]
3. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
4. Prognosis stratification of patients with breast invasive carcinoma based on cysteine metabolism-disulfidptosis affinity.
Zhang Y; Ye Y; Xu A; Luo Y; Sun Y; Zhang W; Ji L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11979-11994. PubMed ID: 37422541
[TBL] [Abstract][Full Text] [Related]
5. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
7. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
8. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
9. A novel anoikis-related gene signature predicts prognosis in patients with breast cancer and reveals immune infiltration.
Tang C; Qin L; Li J
Medicine (Baltimore); 2023 Oct; 102(43):e35732. PubMed ID: 37904416
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer.
Zhang H; Yu X; Yang J; He G; Zhang X; Wu X; Shen L; Zhou Y; Cheng X; Liu X; Zhu Y
Front Immunol; 2022; 13():933779. PubMed ID: 36090993
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.
Li C; Zhang Y
BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Tang W; Xu F; Zhao M; Zhang S
BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract][Full Text] [Related]
16. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
[TBL] [Abstract][Full Text] [Related]
17. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
Li L; Yang W; Jia D; Zheng S; Gao Y; Wang G
Breast Cancer; 2023 Jul; 30(4):666-684. PubMed ID: 37178414
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Genes to Construct a Novel Prognostic Model of Breast Cancer: A Chemosensitivity-Based Study.
Deng ZM; Hu W; Dai FF; Yuan MQ; Hu M; Cheng YX
Front Immunol; 2021; 12():734745. PubMed ID: 34764953
[TBL] [Abstract][Full Text] [Related]
20. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer.
Hua H; Zheng C; Fan J; Li X; Xie W; Chen J; Yu C
Biomed Res Int; 2022; 2022():1916787. PubMed ID: 36518628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
